P2.086 Origins of Repeat Infections with Chlamydia Trachomatis (Ct) Among Heterosexual Men in Two Southern Cities in the United States

Abstract

Poster presentations weeks, with flattening of the lesions on the glans. All lesions were noted by the patient to have cleared after four weeks of imiquimod use, and only post inflammatory hyperpigmentation was noted at his review after six weeks. Minimal side effects were noted by the patient except for transient itch. Discussion We report our first case of penile bowenoid papulosis responding to imiquimod monotherapy, and is the 5th reported case to date. Our case demonstrates one of the most rapid clinical clearance within six weeks, after only four weeks of imiquimod application. Other treatment modalities like electrocurrettage, 5-fluorouracil or topical interferon have all been associated with recurrence. Immunomodulatory treatment for this condition appears safe and efficacious, with the added convenience of being patient administered.

Azithromycin Treatment Failure for Chlamydia trachomatis Among Heterosexual Men With Nongonococcal Urethritis

“…[8–10] The secondary data analysis was approved by the Institutional Review Boards of all participating institutions. Common inclusion criteria for all studies were English speaking men who had sex with a women in the last 2–3 months, attended an STD clinic, were diagnosed with NGU and had a positive test for Ct in urine or urethral swab test using the Aptima Combo 2 assay (Hologic/Gen-Probe Inc.) Analyses were limited to men who were treated with 1 g azithromycin under direct observation therapy and retested post treatment using the same assay for a urine specimen.…”

“…Study 1 [8] was a cohort study conducted from January 2011 to July 2013 in New Orleans, Louisiana and Jackson, Mississippi. Men were at least 18 years old and had sex with at least 1 woman in the 2 months prior to enrollment.…”

“…[8–10] Differences in rates could be attributed to test of cure (TOC) measurement issues, variable rates of post-treatment sexual exposure, or geographic variability in azithromycin susceptibility.…”